Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Sep 30, 2010

Premium

Title: RNAi Expression Constructs

Patent Number: 7,803,611

Filed: Feb. 3, 2006

Lead Inventor: Petrus Roelvink, Benitec

The invention, the patent's abstract states, "provides compositions and methods suitable for expressing 1-x RNAi agents against a gene or genes in cells, tissues, or organs of interest in vitro and in vivo so as to treat diseases or disorders.


Title: Modulation of Growth Hormone Receptor Expression and Insulin-Like Growth Factor Expression

Patent Number: 7,803,781

Filed: Feb. 26, 2004

Lead Inventor: Kenneth Dobie, Isis Pharmaceuticals

The patent, its abstract states, claims "compounds, compositions, and methods … for modulating the expression of growth hormone receptor and/or insulin like growth factor-I. The compositions comprise oligonucleotides targeted to nucleic acid encoding growth hormone receptor. Methods of using these compounds for modulation of growth hormone receptor expression and for diagnosis and treatment of disease associated with expression of growth hormone receptor and/or insulin-like growth factor-I are provided. Diagnostic methods and kits are also provided."


Title: Intravenous Delivery of Polynucleotides to Cells in Mammalian Limb

Patent Number: 7,803,782

Filed: May 27, 2004

Lead Inventor: James Hagstrom, Mirus Bio (Roche)

The invention, the patent's abstract states, comprises an "intravenous delivery method … that enables delivery of polynucleotides to extravascular cells of a mammalian limb. The method involves the injection of polynucleotides into a distal vein of a limb that is transiently occluded. Polynucleotide delivery is facilitated by rapid injection in sufficient volume to enable extravasation of the solution into surrounding tissue."


Title: siRNA Targeting TATA Box Binding Protein-Associated Factor

Patent Number: 7,803,933

Filed: Nov. 12, 2009

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for TAF1."


Title: Bacterial-Mediated TNF-Alpha Gene Silencing

Application Number: 20100239546

Filed: June 13, 2008 PCT Filed: June 13, 2008

Lead Inventor: Johannes Fruehauf, Beth Israel Deaconess Medical Center (Marina Biotech)

The patent application, its abstract states, claims "methods … for the delivery of one or more small interfering RNAs to a eukaryotic cell using a bacterium. Methods are also described for using this bacterium to regulate gene expression in eukaryotic cells using RNA interference, and methods for treating an inflammatory disease or disorder. The bacterium includes one or more siRNAs or one or more DNA molecules encoding one or more siRNAs. Vectors are also described for use with the bacteria of the invention for causing RNA interference in eukaryotic cells."


Title: microRNA Antisense PNAs, Compositions Comprising the Same, and Methods for Using and Evaluating the Same

Application Number: 20100240058

Filed: Nov. 24, 2008 PCT Filed: Nov. 24, 2008

Lead Inventor: Hee Kyung Park, Panagene

The invention, the patent application's abstract states, comprises "a microRNA antisense [peptide nucleic acid] capable of inhibiting the activity or function of microRNA, a composition for inhibiting the activity or function of microRNA containing the same, a method for inhibiting the activity or function of microRNA using the same, and a method for evaluating the effectiveness thereof."


Title: siRNA Targeting Glucagon Receptor

Application Number: 20100240554

Filed: April 13, 2010

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," according to the patent application's abstract. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for GCGR."


Title: RNA Interference-Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid

Application Number: 20100240730

Filed: March 26, 2010

Lead Inventor: Leonid Beigelman, Sirna Therapeutics (Merck)

The invention, the patent application's abstract states, "concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, cosmetic, cosmeceutical, prophylactic, diagnostic, target validation, and genomic-discovery applications.

"Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules … capable of mediating RNA interference against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of disease (e.g., cancer, proliferative, inflammatory, metabolic, autoimmune, neurologic, ocular diseases), condition, trait (e.g., hair growth and removal), genotype and phenotype that responds to modulation of gene expression or activity in a cell, tissue, or organism. Such small nucleic acid molecules can be administered systemically, locally, or topically."


Title: Lipopeptides for Delivery of Nucleic Acids

Application Number: 20100240731

Filed: March 30, 2010

Lead Inventor: Roger Adami, MDRNA (Marina Biotech)

The invention, the patent application's abstract states, comprises "lipopeptide compounds [with] a peptide having 2 to 100 amino acid residues, and having a lipophilic group attached to at least one terminus of the peptide or to at least one amino acid residue of the peptide, and salts and uses thereof. The lipophilic group may be attached to the N-terminus, C-terminus, or both termini of the peptide. The lipophilic group may be attached to at least one internal amino acid residue. …The lipophilic group may be attached to either termini or both and at least one internal amino acid residue."


Title: Aptamer-Targeted siRNA to Prevent Attenuation or Suppression of a T Cell Function

Application Number: 20100240732

Filed: April 1, 2010

Inventor: Eli Gilboa, University of Miami

The invention, the patent application's abstract states, comprises "compositions for countering immune attenuating/suppressive pathways comprise targeting agents or aptamer-targeted RNAi-mediated gene silencing. These compositions have broad applicability in the treatment of many diseases."


Title: Methods and Compositions for Specific Inhibition of Gene Expression by Double-Stranded RNA

Application Number: 20100240734

Filed: June 1, 2010

Lead Inventor: John Rossi, City of Hope (Integrated DNA Technologies)

"The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene," the patent application's abstract states. "More particularly, the invention is directed to compositions that contain double-stranded RNA, and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery."


Title: Therapeutic Compositions

Application Number: 20100240881

Filed: March 10, 2010

Lead Inventor: Muthiah Manoharan, Alnylam Pharmaceuticals

The patent application, its abstract states, "relates to therapeutic siRNA agents and methods of making and using the agents."

The Scan

Back as Director

A court has reinstated Nicole Boivin as director of the Max Planck Institute for the Science of Human History, Science reports.

Research, But Implementation?

Francis Collins reflects on his years as the director of the US National Institutes of Health with NPR.

For the False Negatives

The Guardian writes that the UK Health Security Agency is considering legal action against the lab that reported thousands of false negative COVID-19 test results.

Genome Biology Papers Present Epigenetics Benchmarking Resource, Genomic Architecture Maps of Peanuts, More

In Genome Biology this week: DNA methylation data for seven reference cell lines, three-dimensional genome architecture maps of peanut lines, and more.